---
schema_version: "secwatch.filing_event.v1"
accession: "0001367644-25-000054"
form_type: "8-K"
ticker: "EBS"
cik: "0001367644"
company_name: "Emergent BioSolutions Inc."
filed_at: "2025-03-10T23:59:59+00:00"
generated_at: "2026-05-25T00:59:08.015182+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Emergent BioSolutions sells Baltimore-Bayview manufacturing site to Syngene for $36.5M

## Summary
- Sale of Bayview drug substance manufacturing facility to Syngene Intl for ~$36.5M; closing expected Q1 2025.
- Emergent retains rights to secure manufacturing services and capacity at the facility for growth and pandemic response.
- Emergent continues streamlined manufacturing network with facilities in Lansing, MI and Winnipeg, MB.
- Bayview site received FDA 'No Action Indicated' (NAI) inspection outcome in March 2024.
- CEO Joe Papa states sale advances multi-year transformation plan and turnaround phase.

## SEC filing metadata
- accession: 0001367644-25-000054
- form_type: 8-K
- ticker: EBS
- cik: 0001367644
- company_name: Emergent BioSolutions Inc.
- filed_at: 2025-03-10T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1367644/000136764425000054/0001367644-25-000054-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1367644/000136764425000054/ebs-20250310.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001367644-25-000054
- JSON: https://secwatch.observer/filing/0001367644-25-000054.json
- Plain text: https://secwatch.observer/filing/0001367644-25-000054.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.